Press release
Peptic Ulcer Drugs Market Value to Reach US$ 54.8 Bn by 2032 Driven by Rising GI Disorders
Peptic Ulcer Drugs Market
The global peptic ulcer drugs market is witnessing steady expansion due to a rising incidence of gastrointestinal disorders, growing awareness, and increasing adoption of combination therapies. The market is poised to grow from US$ 42.6 Bn in 2025 to US$ 54.8 Bn by 2032, exhibiting a CAGR of 3.2% from 2025 to 2032. This moderate yet sustained growth reflects the increasing global healthcare burden caused by Helicobacter pylori infections, prolonged NSAID usage, stress-related gastrointestinal issues, and lifestyle-related dietary changes.
The proton pump inhibitors (PPIs) segment is anticipated to remain the leading product category due to their effectiveness in reducing gastric acid production. Regionally, North America holds the largest share of the market, attributed to its robust healthcare infrastructure, widespread access to advanced treatments, and high prevalence of lifestyle-related gastric issues. The Asia Pacific region is expected to witness rapid growth owing to improving healthcare access, rising disposable incomes, and higher disease awareness.
Get a Sample PDF Brochure of the Report (Use Corporate Email ID for a Quick Response): https://www.persistencemarketresearch.com/samples/3704
✅ Key Highlights from the Report
➤ The global peptic ulcer drugs market is expected to reach US$ 54.8 Bn by 2032.
➤ Proton pump inhibitors (PPIs) dominate the product type segment.
➤ North America leads the market due to advanced healthcare and high prevalence rates.
➤ Asia Pacific is projected to witness the fastest growth during the forecast period.
➤ Hospital pharmacies remain the leading distribution channel segment.
➤ Rising prevalence of H. pylori and NSAID-induced ulcers fuel market demand.
Read More For Peptic Ulcer Drugs Market: https://www.persistencemarketresearch.com/market-research/peptic-ulcer-drugs-market.asp
✅ Frequently Asked Question:
What is the most effective treatment for peptic ulcers?
The most effective treatment for peptic ulcers generally involves a combination of antibiotics and proton pump inhibitors (PPIs). When an ulcer is caused by Helicobacter pylori, a bacterium commonly found in the stomach lining, physicians typically prescribe a combination therapy called triple therapy. This includes two antibiotics (commonly amoxicillin and clarithromycin) to eliminate the bacteria, and a PPI like omeprazole or esomeprazole to reduce stomach acid and allow the ulcer to heal.
PPIs are preferred over H2-receptor antagonists due to their superior acid suppression and longer duration of action. In cases where the ulcer is drug-induced, such as from nonsteroidal anti-inflammatory drugs (NSAIDs), discontinuing the offending medication and switching to alternative pain management options are also recommended. Lifestyle modifications including avoiding alcohol, spicy food, and smoking are crucial for effective recovery. In severe cases or recurrent ulcers, endoscopic therapy or surgery may be necessary.
✅ Market Segmentation Analysis
The peptic ulcer drugs market is segmented by drug class into proton pump inhibitors (PPIs), H2-receptor antagonists, antacids, antibiotics, and others. Among these, PPIs dominate due to their long-lasting effects in reducing gastric acid secretion. Antibiotics are essential in treating ulcers caused by H. pylori infection, while antacids are mostly used for symptomatic relief.
In terms of end-users, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. Hospital pharmacies account for the largest share due to the prevalence of inpatient care and prescription-based treatment for severe ulcer cases. Online pharmacies, however, are gaining momentum, particularly in developed and urban regions, due to convenience and availability of OTC drugs.
✅ Regional Insights
North America remains the most dominant region in the global peptic ulcer drugs market, owing to a well-established healthcare ecosystem, early adoption of innovative treatments, and a high prevalence of chronic NSAID usage. The U.S. especially contributes a substantial portion of the regional market share.
Meanwhile, the Asia Pacific region is emerging as a promising market due to increasing gastrointestinal diseases, changing dietary patterns, and a surge in self-medication practices. Rapid urbanization and healthcare reforms in countries like China and India are further propelling market growth.
✅ Market Drivers, Restraints, and Opportunities
Market Drivers
The rising prevalence of Helicobacter pylori infections globally is one of the key growth drivers for the peptic ulcer drugs market. Increased stress levels, smoking, excessive alcohol consumption, and the frequent use of NSAIDs also contribute significantly to ulcer formation. Growing awareness about gastrointestinal health and improved diagnostic rates further support demand for effective treatment options.
Market Restraints
Despite the market's positive outlook, the increasing availability of generic drugs poses a challenge for branded drug manufacturers in terms of profitability. Additionally, the adverse side effects associated with long-term use of PPIs, such as vitamin B12 deficiency and increased fracture risk, can limit their widespread and prolonged use.
Market Opportunities
The rising adoption of e-commerce and telemedicine platforms for drug distribution creates vast opportunities for market players, especially in the post-pandemic digital age. Moreover, the development of novel drug delivery systems and combination therapies for better efficacy and patient compliance offers untapped growth potential.
✅ Reasons to Buy the Report
☑Comprehensive market forecast with CAGR, value projections, and growth drivers up to 2032
☑In-depth segmentation analysis by drug class, distribution channel, and region
☑Evaluation of market dynamics including trends, restraints, and opportunities
☑Coverage of key players, recent developments, and competitive strategies
☑Regional insights highlighting high-growth and emerging markets
✅ Company Insights
✦AstraZeneca PLC
✦Pfizer Inc.
✦Takeda Pharmaceutical Company Limited
✦GlaxoSmithKline plc
✦Johnson & Johnson Services Inc.
✦Bayer AG
✦Eisai Co. Ltd.
✦Abbott Laboratories
✦Cadila Pharmaceuticals
✦Sun Pharmaceutical Industries Ltd.
■In 2023, Pfizer announced advancements in combination therapy research to improve H. pylori eradication success rates.
■Takeda launched a new formulation of Dexilant (dexlansoprazole) for better dosing flexibility and acid control in 2024.
✅ Conclusion
The global peptic ulcer drugs market is steadily advancing, propelled by rising gastrointestinal health concerns, innovation in drug formulations, and improved patient awareness. With increasing adoption of PPIs and combination therapies, the market is expected to maintain a positive trajectory through 2032. While generic competition and side effects present challenges, the emergence of digital health platforms and innovative treatment avenues will likely open new doors for market expansion. Stakeholders should focus on emerging markets, combination therapies, and novel drug delivery solutions to remain competitive in this evolving landscape.
✅About Persistence Market Research:
At Persistence Market Research, we specialize in creating research studies that serve as strategic tools for driving business growth. Established as a proprietary firm in 2012, we have evolved into a registered company in England and Wales in 2023 under the name Persistence Research & Consultancy Services Ltd. With a solid foundation, we have completed over 3600 custom and syndicate market research projects, and delivered more than 2700 projects for other leading market research companies' clients.
Our approach combines traditional market research methods with modern tools to offer comprehensive research solutions. With a decade of experience, we pride ourselves on deriving actionable insights from data to help businesses stay ahead of the competition. Our client base spans multinational corporations, leading consulting firms, investment funds, and government departments. A significant portion of our sales comes from repeat clients, a testament to the value and trust we've built over the years.
Contact Us:
Persistence Market Research
G04 Golden Mile House, Clayponds Lane
Brentford, London, TW8 0GU UK
USA Phone: +1 646-878-6329
UK Phone: +44 203-837-5656
Email: sales@persistencemarketresearch.com
Web: https://www.persistencemarketresearch.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Peptic Ulcer Drugs Market Value to Reach US$ 54.8 Bn by 2032 Driven by Rising GI Disorders here
News-ID: 4111047 • Views: …
More Releases from Persistence Market Research
Global Automotive Active Health Monitoring Systems Market Expected to Surge from …
The Automotive Active Health Monitoring Systems Market is poised for significant growth over the forecast period of 2025 to 2032. This market is projected to expand from USD 683.9 million in 2025 to USD 2,338.3 million by 2032, registering a robust CAGR of 19.20%. Automotive active health monitoring systems are designed to track the real-time status of vehicles, enabling predictive maintenance, reducing downtime, and enhancing overall vehicle safety. With growing…
Primary Packaging Labels Market to Reach US$12.2 Bn by 2031 with Steady Growth a …
➤Overview of the Market
The global primary packaging labels market is a crucial segment of the packaging industry, enabling product identification, regulatory compliance, and brand differentiation. Primary labels are applied directly on product packaging, such as bottles, vials, boxes, and pouches, serving both functional and promotional roles. As consumer awareness of product authenticity and safety continues to rise, demand for innovative labeling solutions is expanding. Moreover, stringent regulatory frameworks in industries…
Shelf Stable Packaging Market to Reach US$10.7 Bn by 2031 with Steady Growth at …
➤Overview of the Market
The shelf stable packaging market plays a critical role in extending the shelf life of food and beverages without the need for refrigeration, ensuring product safety, convenience, and affordability. These packaging solutions-spanning cartons, pouches, cans, and plastic containers-are widely used in ready-to-eat meals, dairy alternatives, sauces, soups, and beverages. Growth in the market is closely linked to evolving consumer lifestyles, increasing urbanization, and demand for long-lasting packaged…
Print Label Market to Reach US$68.6 Bn by 2031 with Steady Growth at 4.3% CAGR - …
➤Overview of the Market
The global print label market is poised for substantial expansion, driven by increasing demand across industries such as food & beverages, pharmaceuticals, cosmetics, and logistics. Labels play a crucial role in brand identity, product differentiation, and regulatory compliance. In addition to providing essential information like product ingredients, expiration dates, and barcodes, printed labels serve as key marketing tools that influence consumer purchase decisions. With the rapid rise…
More Releases for PPI
PPI Market Analysis Current Landscape and Future Outlook
The global PPI market was valued at approximately USD 4.9 billion in 2023 and is projected to reach around USD 7.73 billion by 2032, growing at a compound annual growth rate (CAGR) of 5.2% from 2024 to 2032 .
PPI Market Overview
The PPI market is experiencing steady growth, driven by the increasing prevalence of gastrointestinal disorders such as gastroesophageal reflux disease (GERD), peptic ulcers, and Zollinger-Ellison syndrome. The aging global population…
PPI Market 2024 Trends, Analysis, Growth, Opportunities, Forecast to 2031
The global proton pump inhibitors market is estimated to grow at a significant CAGR during the forecast period. Many researchers have found that proton pump inhibitors have raised the risk of COVID-19 in patients taking these medications. The researchers of the American Journal of Gastroenterology, in 2020, conducted research in which more than 55,000 people taking proton pump inhibitors participated, out of which 3,476 said that they had tested positive…
FSA Gives Banks Extension to Deal with 2011 PPI Claims
The Financial Services Authority (FSA) has given high street banks more time to deal with payment protection insurance (PPI) mis-selling claims.
The FSA has given banks
Under FSA rules PPI complaints have to be responded to within eight weeks.
The extension gives firms time to deal with claims which had been put on hold. It has also given more time for the firms to deal with PPI complaints received since the…
PPI Claims Delayed By Banks But This Time The FSA Stand Firm
Many customers will remember with some sorrow the manner in which the bank charges fiasco turned into an ultimately unfortunate defeat for many consumers. The banks halted the stem of complaints by lodging a test case against the Office of Fair Trading and the FSA at the time issued a waiver to allow all bank charges complaints to be kept on hold.
In 2010 following countless assessments and investigations, the FSA…
Mis-sold PPI - The Worst Personal Finance Scandal Ever?
New information released by the Financial Services Authority (FSA) could see mis-sold PPI become the worst ever personal finance scandal to hit Britain.
The FSA believes it will receive 2.75 million complaints about mis-sold PPI over the next five years. Compensation to the customers who have been mis-sold PPI policies is expected to top £4 billion.
Could mis-sold PPI become Britain's worst ever personal finance scandal? If the level of complaints…
PPI Most Complained About Financial Problem
FOR IMMEDIATE RELEASE
London, UK, 16th September, 2010: Payment Protection Insurance (PPI) was the most complained about financial issue in the first half of 2010, according to new figures.
The Financial Ombudsman Service (FOS) has received 30,000 complaints from consumers who have been mis-sold the policies.
The body received three times more complaints about PPI than the combined totals for mortgages, investments, and pensions.
Overall, 84,212 new complaints were made to the FOS about…
